Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase II study of bortezomib maintenance therapy in transplant-ineligible multiple myeloma patients
KCT0003841Phase 2Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- May 2017
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Seoul St. Mary's Hospital. Started May 2017; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0003841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003841.